Osteopenia Management Guidelines

Assessment and Risk Stratification

The American College of Clinical Oncology recommends calculating fracture risk using the FRAX tool to guide treatment decisions for patients with osteopenia 1, 2
Bone mineral density (BMD) testing with dual-energy x-ray absorptiometry (DXA) is recommended when one or more risk factors for osteoporotic fracture are present, with the preferred assessment using DXA of total spine, hip, and femoral neck 3, 4, 5
The National Osteoporosis Foundation suggests repeating DXA every 2 years or annually if medically indicated, but not more frequently than annually 3, 1

The American College of Clinical Oncology recommends ensuring adequate calcium intake of 1,000-1,200 mg/day through diet or supplements for patients with osteopenia 3, 1, 2
Optimizing vitamin D intake of 600-800 IU/day, with a target serum level ≥20 ng/ml, is recommended for patients with osteopenia 1, 2
Engaging in regular weight-bearing and resistance exercises is beneficial for patients with osteopenia 3, 6, 1
Implementing fall prevention strategies is recommended for patients with osteopenia 6, 1

The American College of Clinical Oncology recommends initiating bone-modifying agents when the FRAX calculation shows a 10-year risk of hip fracture ≥3% or major osteoporotic fracture ≥20% 3, 4, 1
Bone-modifying agents should be initiated in patients with significant osteopenia and additional risk factors, or a history of prior osteoporotic fracture that has not been treated 3, 5
Patients on long-term glucocorticoid therapy, particularly at doses >7.5 mg/day of prednisone, should be considered for bone-modifying agents 2

Oral bisphosphonates, such as alendronate, are first-line therapy due to safety, cost, and efficacy for patients with osteopenia 1, 2
Alternative options, such as IV bisphosphonates or denosumab, may be considered if oral bisphosphonates are not appropriate 3, 2, 1

Cancer survivors may have baseline risks for osteoporosis plus added risks from treatment-related bone loss, and should be considered for earlier intervention 3, 4
Bisphosphonates have been shown to preserve bone density in premenopausal women receiving chemotherapy 4, 5

Patients with cirrhosis or severe cholestasis should have BMD testing, and additional assessment for vitamin D deficiency, thyroid function, and hypogonadism should be considered 6
Calcium and vitamin D supplementation is recommended for all patients with chronic liver disease 6

Osteopenia is present in 40-50% of IBD patients, and weight-bearing exercise, smoking cessation, and maintaining adequate dietary calcium are beneficial 7
Calcium and vitamin D are recommended if T-score is less than -1.5 7

If pharmacological therapy is deferred, repeat DXA in 2 years or in 1 year if medically indicated, and monitor BMD every 2 years to assess response for patients on treatment 3, 5, 1
Assess medication adherence regularly, as non-adherence is common and reduces treatment effectiveness 1

Smoking cessation and limiting alcohol consumption (maximum 1-2 drinks per day) is recommended for patients with osteopenia, as part of lifestyle modifications to improve bone density 8
Maintaining weight in the recommended range is important, as low body mass index is an independent risk factor for osteopenia 8
For patients with chronic liver disease, calcium (1,000-1,500 mg/day) and vitamin D (400-800 IU/day) supplementation is recommended to support bone health 8

Take oral bisphosphonates (such as alendronate) on an empty stomach in the morning, 0.5–2 hours before food and other drugs, and at a different time to calcium supplements, to maximize efficacy 8
History of fragility fracture is a consideration for pharmacological therapy, particularly with oral bisphosphonates or other medications 8

Patients with cirrhosis or severe cholestasis should have BMD testing, and avoid anabolic steroids as they can cause abnormal liver biochemistry 8